How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Improving stability and secretion of antibodies

Organization name

Bayerische Patentallianz GmbH

Profile

Background

Antibodies represent one of the most important groups of proteins in the field of biotechnology. They are not only used in basic research but are also exploited for diagnostic and therapeutic purposes such as cancer treatment. However, due to their complex folding and assembly, production of antibodies for experimental and medical use is expensive. Hence, improving antibody properties is of high commercial interest. The constant domain of the antibody light chain (CL) is essential for both folding of the heavy chain CH1 domain and consequently also for quality control of correct antibody assembly. Since the CH1 domain can only adopt its native conformation after association with the CL domain, mutations in CL may have an impact on the efficiency of assembly and secretion of antibodies.

Innovation

Here, we present an invention that improves the biophysical properties of antibodies and therefore results in increased secretion. In line with this technology, the CL domain is modified by introducing two intra-molecular changes
whereby a significant stabilization is achieved.

Compared to the wild type CL, the melting point of the modified CL domain is almost 10┬░C higher and its stability against urea-induced denaturation is also markedly increased. Notably, when light chains comprising this optimized CL domain were co-expressed with Ig heavy chains, a significant increase in the assembly and subsequent secretion of complete IgG antibody molecules from mammalian cells was observed. Although this technology was established using IgG, it is applicable to all classes of antibodies because of the ubiquitous presence of CL in all immunoglobulin classes. Furthermore, the invention will also be applicable for the optimization of other constant domains besides CL.

Commercial Opportunities

  • Antibodies have a broad field of application (basic research, diagnostics, therapy) but high costs of production
  • USP: antibodies with significantly higher stability and strongly increased secretion
  • Target groups for technology: Antibody manufacturer, CMOs

Developmental Status

Proof of concept in cell culture

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries